1-[2-(Methanesulfonyl)ethyl]-4-(5-methoxy-2-methyl-4-nitrophenyl)piperazine → 5-Methyl-2-(methyloxy)-4-{4-[2-(methylsulfonyl)ethyl)-1-piperazinyl}aniline
반응식
[CH3:1][C:2]1[CH:7]=[C:6]([N+:8]([O-])=O)[C:5]([O:11][CH3:12])=[CH:4][C:3]=1[N:13]1[CH2:18][CH2:17][N:16]([CH2:19][CH2:20][S:21]([CH3:24])(=[O:23])=[O:22])[CH2:15][CH2:14]1>CCOC(C)=O.CO>[CH3:1][C:2]1[C:3]([N:13]2[CH2:14][CH2:15][N:16]([CH2:19][CH2:20][S:21]([CH3:24])(=[O:22])=[O:23])[CH2:17][CH2:18]2)=[CH:4][C:5]([O:11][CH3:12])=[C:6]([CH:7]=1)[NH2:8]참가 물질
실험 절차
1-[2-methyl-5-(methyloxy)-4-nitrophenyl]-4-[2-(methylsulfonyl)ethyl]piperazine from a separate batch (0.257 g, 0.72 mmol) was placed in a 40 mL high vial and dissolved in 10 mL of 1 to 1 EtOAc/MeOH. 5 wt % Platinum(sulfided)/carbon (0.165 g, 0.043 mmol) was added followed quickly by a screw cap septum. The vial was evacuated and filled with N2 six times to remove any oxygen. The vial was then pressurized with H2 (balloon). The solution stirred overnight. The next morning the vessel was evacuated and filled with N2 six times to remove any H2. The solution was filtered through celite and evaporated to afford the title compound of step D (0.194 g, 0.59 mmol, 82%). 1H NMR (400 MHz, CDCl3) δ ppm 6.54 (s, 2H), 3.80 (s, 3H), 3.30-3.37 (m, 2H), 3.07 (s, 3H), 2.91-2.98 (m, 6H), 2.82-2.90 (m, 4H), 2.15 (s, 3H).
후처리
- customcap septum
- customThe vial was evacuated
- additionfilled with N2 six times
- customto remove any oxygen
- customThe next morning the vessel was evacuated
- additionfilled with N2 six times
- customto remove any H2
- filtrationThe solution was filtered through celite
- customevaporated
출처 및 근거
- ORD 기록
- ord-e30bd48eff5c4883a8e46eb375b096b6
- 출처 데이터셋
- uspto-grants-2012_01
- 특허 번호
- US08093239B2
반응 노트
불러오는 중…